Harnessing neutrophils to improve the efficacy of immune checkpoint inhibitors in breast cancer
Harnessing neutrophils to improve the efficacy of immune checkpoint inhibitors in breast cancer
批准号:
10644508
负责人:
Yang Gao
金额:
$11.73万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-06-08 至 2025-05-31
关键词:
Adoptive TransferAdvocateAmericanBasic ScienceBioinformaticsBiologicalBiological MarkersBlood specimenBreastBreast Cancer ModelBreast Cancer PatientCancer EtiologyCancer PatientCell physiologyCellsCessation of lifeCitiesClinicClinicalClinical ResearchClinical TrialsCollaborationsCombined Modality TherapyDataDedicationsDevelopmentDistantEducational workshopEnvironmentFeedbackFoundationsGenesGoalsHospitalsHumanIFNAR1 geneIFNGR1 geneImmuneImmune checkpoint inhibitorImmunityImmunologic MemoryImmunologyImmunophenotypingImpairmentIn VitroInstitutionInterferon alphaInterferonsJournalsKnock-outKnowledgeKnowledge acquisitionLigandsMacrophageMalignant NeoplasmsMalignant neoplasm of lungMediatingMedicalMedical centerMedicineMesotheliomaModelingMouse Mammary Tumor VirusMusMutationMyelogenousOutcomeParabiosisPatientsPhasePostdoctoral FellowPre-Clinical ModelPrediction of Response to TherapyProteinsRenal Cell CarcinomaResearchResearch PersonnelResistanceRoleSamplingSignal TransductionSiteSpatial DistributionT-Cell ProliferationT-LymphocyteTestingTexasTherapeutic InterventionTrainingTranslational ResearchTumor SubtypeWomananti-PD-1anti-PD1 therapyanti-tumor immune responsecancer cellcancer typecareercareer developmentcell typecheckpoint therapychemotherapyclinical applicationclinical biomarkersclinical remissioncollegeeffective therapyexperimental studygain of functiongenetic signatureimmune functionimprovedin vivoinhibitor therapyloss of functionmalignant breast neoplasmmeetingsmultidisciplinaryneoplastic cellneutrophilnext generationnovelnovel markerpatient responseperipheral bloodpolyoma middle tumor antigenpredicting responsepredictive markerprogrammed cell death protein 1receptorresearch and developmentresponders and non-respondersresponseskillstherapeutic developmenttherapeutic targettraining opportunitytranscriptometranscriptomicstranslational cancer researchtranslational studytriple-negative invasive breast carcinomatumor
中文摘要
项目摘要
乳腺癌是最常见的癌症,也是癌症相关死亡的第二大原因。
美国女人多年来免疫检查点抑制剂(ICI)靶向检查点蛋白,如
程序性细胞死亡蛋白1(PD 1)在一部分癌症患者中导致持久的临床缓解,
包括乳腺癌然而,大多数患者对ICI治疗没有反应,因此需要
可以预测患者反应的新型生物标志物和可以提高疗效的治疗靶点,
ICI的持久性。本提案的目标是研究如何克服ICI抗性。我的初步
数据显示,干扰素(IFN)-α和-γ信号在肿瘤和血液中性粒细胞中富集,
对ICIs无反应的人该建议的中心假设是,具有肿瘤诱导的中性粒细胞,
增加的IFN信号传导介导乳腺癌对ICI的抗性,并且可以用作预测性生物标志物。
在K99阶段,我将探索嗜中性粒细胞限制性IFN信号对肿瘤对ICI反应的影响。
并表征嗜中性粒细胞特异性干扰素刺激基因(ISG)特征(Aim 1)。因为我们发现
外周血中性粒细胞中的ISG可以预测乳腺癌对抗PD 1治疗的反应,我将确定是否
血液嗜中性粒细胞ISGs特征可以作为其他癌症类型和人类患者样本中的生物标志物
来自临床和临床试验(Aim 2、K99和R 00)。最后,我将研究中性粒细胞IFN信号在调节
免疫记忆和对ICI的持久应答(目标3,R 00)。在成功完成具体目标后,
这项翻译研究将扩展我们对中性粒细胞IFN信号传导的认识,并为
ICI疗法和克服ICI耐药性的治疗靶点。
我的总体职业目标是建立一个独立的转化癌症研究小组,
了解癌症的发展,确定新的有效疗法,并培养下一代癌症
研究人员K99阶段的这项拟议研究将在莱斯特和苏史密斯乳腺中心进行。
在贝勒医学院,一个高度协作和多学科的环境与强大的整合,
基础、转化和临床研究。该机构致力于博士后的职业发展
学员,并提供各种培训场所,包括生物信息学和免疫学,每周研讨会,
研发研讨会、期刊俱乐部和年度务虚会。德克萨斯州医疗中心是美国最大的
世界上最大的医疗城市,由60多家医疗机构和医院组成,为我提供了巨大的
培训和合作的机会。最后,我将每周与罗森博士和张博士会面,讨论我的
除了我们每周的实验室会议外,我们还每三个月举行一次正式的委员会会议,
我的进步和收到反馈。我还得到了一位患者倡导者和其他合作者的支持。通过
在K99/R 00申请中提出的培训和研究计划,我将获得知识和技能,
将极大地提高我作为一名独立调查员开展科学事业的能力。
英文摘要
Project Summary
Breast cancer has been the most prevalent cancer and the second leading cause of cancer-related death in
American women for many years. Immune checkpoint inhibitors (ICIs) targeting checkpoint proteins such as
programmed cell death protein 1 (PD1) resulted in durable clinical remissions in a subset of cancer patients,
including breast cancer. However, most patients didn’t show a response to ICI treatment, urging the need for
novel biomarkers that can predict patient response and therapeutic targets that can improve the efficacy and
durability of ICIs. The goal of this proposal is to investigate how to overcome the ICI resistance. My preliminary
data showed that interferon (IFN) -alpha and -gamma signaling are enriched in the tumor and blood neutrophils
of nonresponders to ICIs. The central hypothesis of this proposal is that tumor-educated neutrophils with
increased IFN signaling mediate breast cancer resistance to ICIs, and can be used as predictive biomarkers.
During the K99 phase, I will explore the impact of neutrophil-restricted IFN signaling on tumor response to ICIs
and characterize the neutrophil-specific interferon-stimulated gene (ISG) signature (Aim 1). Since we found that
ISGs in peripheral blood neutrophils can predict breast cancer response to anti-PD1 therapy, I will determine if
blood neutrophil ISGs signature can serve as a biomarker in other cancer types and human patient samples
from the clinic and clinical trials (Aim 2, K99 and R00). Finally, I will study the neutrophil IFN signaling in regulating
immune memory and durable response to ICIs (Aim 3, R00). Upon successful completion of the Specific Aims,
this translational study will extend our knowledge of neutrophil IFN signaling and provide novel biomarkers for
the ICI therapy and therapeutic targets to overcome the ICI resistance.
My overall career goal is to establish an independent translational cancer research group that will improve
understanding of cancer development, identify novel effective therapies, and train the next generation of cancer
researchers. This proposed research in the K99 phase will take place in the Lester and Sue Smith Breast Center
at Baylor College of Medicine, a highly collaborative and multidisciplinary environment with strong integration of
basic, translational, and clinical research. The institution is dedicated to the career development of postdoctoral
trainees, and provides a variety of training venues including bioinformatics and immunology, weekly seminars,
R&D workshops, journal clubs, and the annual retreat. BCM is part of the Texas Medical Center, the largest
medical city in the world consisting of over 60 medical institutions and hospitals, which offers me enormous
opportunities for training and collaboration. Finally, I will meet with Drs. Rosen and Zhang weekly to discuss my
projects besides our weekly lab meetings and have a formal committee meeting every three months to discuss
my progress and receive feedback. I am also supported by a patient advocate and other collaborators. Through
the training and research plan proposed within my K99/R00 application, I will acquire knowledge and skills which
will greatly improve my ability to launch my scientific career as an independent investigator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structural basis of replisome mediated DNA replication and repair
-
批准号:10620204
-
项目类别:
-
资助金额:$38.43万
-
财政年份:2021
-
负责人:Yang Gao
-
依托单位:
Structural basis of replisome mediated DNA replication and repair
-
批准号:10455616
-
项目类别:
-
资助金额:$38.43万
-
财政年份:2021
-
负责人:Yang Gao
-
依托单位:
Structural basis of replisome mediated DNA replication and repair
-
批准号:10275032
-
项目类别:
-
资助金额:$38.43万
-
财政年份:2021
-
负责人:Yang Gao
-
依托单位:
海外基金